According to EvaluatePharma, there is going to be some reshuffling of the top pharma rankings . It is estimated that in 2018, Novartis will be overtaking Pfizer as the top pharmaceutical company (ranked by prescription-drug revenue), with Sanofi coming in third position. Runner-ups include GlaxoSmithKline, Roche and Merck & Co. respectively. The top 6 pharmas are estimated to enjoy sales of $40 billion or more and the rest through No.11, NovoNordisk, are estimated to be in the $20+ billion sales range.
Yet, these top rankers are not the fastest growing drugmakers. HIV drugmaker Gilead Sciences earns the honour as the fastest-growing pharma with a compound annual growth rate of 9%, diabetes specialist Novo Nordisk coming in second with 7%, and GlaxoSmithKline and Takeda coming in third, each with 4%.
Despite the encouraging figures, majority of drugmakers global market share will decrease. Novartis will be holding the biggest share of 5.8%, although lesser than the 6.5% last year.
More rankings below:
Top Selling Drug
- Diabetes-drug Januvia, Merck
- Anti-TNF durg, Abbott Laboratories
Top 6 Pharmas in 2018, Ranked by Prescription-Drug Revenue
- Merck & Co
- Gilead Sciences
- Novo Nordisk
- GlaxoSmithKline, Takeda
Top Pharmas in 2018, Ranked by Biotech Sales
- Novo Nordisk
Most Valuable R&D Project: Bristol-Myers Squibb and Pfizer’s clot-fighter Eliquis
Want to know more about the Trends and Developments of the BioPharmaceutical Industry?
Join the likes of Eisai, Astrazeneca, Roche and other global industry leaders at the upcoming Drug Discovery World Asia 2013 and learn how to re-formulate your R&D strategies for increased speed to market and profitability.
As part of Asia's largest life science industry gathering, BioPharma Asia Convention 2013 will be held on18 – 21 March 2013 at Marina Bay Sands, Singapore.
To find out more about speaking opportunities available at this conference, contact Gladys Leong at email@example.com or +65 6322 2705.